RVPH — REVIVA PHARMACEUTICALS HOLDINGS, INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1742927 ·
Last close
$0.44
Market Cap
$5.74M
52W High
$0.91
52W Low
$0.26
ADV30
56,545
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,271,952 | -3,195,987 | 23,559,636 | 22,190,231 | 6,119,155 |
| Dec 2025 | 0 | — | -3,559,041 | -3,367,679 | 15,923,198 | 14,438,792 | 7,275,553 |
| Sep 2025 | 0 | — | -4,029,841 | -4,010,773 | 14,332,649 | 13,183,259 | 9,782,914 |
| Jun 2025 | 0 | — | -6,072,982 | -6,053,610 | 11,634,846 | 10,363,714 | 12,093,993 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,201,741
Investing CF
—
Financing CF
$37,102,568
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.67
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-187,333,939
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-16,602,592
Pretax Income TTM
$-16,611,027
Interest Exp TTM
$8,435
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,200,031 | -19,864,902 | 15,923,198 | 7,275,553 | — | -24,594,643 |
| Dec 2024 | 0 | -30,798,889 | -29,918,802 | 15,503,088 | 14,690,516 | — | -33,543,916 |
| Dec 2023 | 0 | -39,503,636 | -39,260,837 | 23,700,388 | 17,981,672 | — | -28,324,353 |
| Dec 2022 | 0 | -28,228,758 | -28,261,442 | 18,923,675 | 10,529,429 | — | -18,960,581 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.90
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XBIO | Xenetic Biosciences, Inc. | $5.81M | $2.54 | — |
| CURX | Curanex Pharmaceuticals Inc | $5.81M | $0.20 | — |
| GELS | Gelteq Ltd | $5.57M | $0.52 | — |
| PCSA | Processa Pharmaceuticals, Inc. | $5.95M | $2.15 | — |
| NCNA | NuCana plc | $5.49M | $1.32 | — |
News headlines (Yahoo Finance, 1h cache)
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
2026-06-26 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
2026-06-23 12:35 · Yahoo
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
2026-06-23 12:00 · Yahoo
RVPH: First Quarter 2026 Results
2026-05-27 10:55 · Yahoo
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
2026-05-18 12:00 · Yahoo
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 20:35 · Yahoo
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
2026-04-23 12:00 · Yahoo
Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans
2026-04-21 02:46 · Yahoo
RVPH: Shareholder Letter Introduces New IP
2026-04-20 09:30 · Yahoo
Reviva Announces Letter to Shareholders
2026-04-15 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.